EA201991116A1 - Полинуклеотиды и полипептиды аденовируса - Google Patents
Полинуклеотиды и полипептиды аденовирусаInfo
- Publication number
- EA201991116A1 EA201991116A1 EA201991116A EA201991116A EA201991116A1 EA 201991116 A1 EA201991116 A1 EA 201991116A1 EA 201991116 A EA201991116 A EA 201991116A EA 201991116 A EA201991116 A EA 201991116A EA 201991116 A1 EA201991116 A1 EA 201991116A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptides
- polynucleotides
- adenovirus
- adenovirus polynucleotides
- sequences
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 4
- 108091033319 polynucleotide Proteins 0.000 title abstract 4
- 239000002157 polynucleotide Substances 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 241001217856 Chimpanzee adenovirus Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620968.6A GB201620968D0 (en) | 2016-12-09 | 2016-12-09 | Adenovirus polynucleotides and polypeptides |
| PCT/IB2017/057738 WO2018104911A1 (en) | 2016-12-09 | 2017-12-07 | Adenovirus polynucleotides and polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991116A1 true EA201991116A1 (ru) | 2019-12-30 |
Family
ID=58222021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991116A EA201991116A1 (ru) | 2016-12-09 | 2017-12-07 | Полинуклеотиды и полипептиды аденовируса |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11414679B2 (https=) |
| EP (1) | EP3551224A1 (https=) |
| JP (1) | JP2020511114A (https=) |
| KR (1) | KR20190092471A (https=) |
| CN (1) | CN110300597A (https=) |
| AR (1) | AR110502A1 (https=) |
| AU (1) | AU2017371944B2 (https=) |
| BE (1) | BE1025029B1 (https=) |
| BR (1) | BR112019010906A2 (https=) |
| CA (1) | CA3045973A1 (https=) |
| EA (1) | EA201991116A1 (https=) |
| GB (1) | GB201620968D0 (https=) |
| IL (1) | IL266942A (https=) |
| MX (1) | MX2019006725A (https=) |
| WO (1) | WO2018104911A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| EP3655536A1 (en) * | 2017-07-17 | 2020-05-27 | GlaxoSmithKline Biologicals SA | Lyssavirus antigen constructs |
| WO2019076877A1 (en) * | 2017-10-16 | 2019-04-25 | Glaxosmithkline Biologicals Sa | ADENOVIRAL VECTORS FOR REPLICATION |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| EP3807298A1 (en) * | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| US12227754B2 (en) * | 2020-04-07 | 2025-02-18 | Lung Biotechnology Pbc | Adenoviral expression vector and methods and cell lines for production |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| CN119677860A (zh) * | 2022-06-22 | 2025-03-21 | 阿斯克肋匹奥生物制药公司 | 基于腺病毒的核酸及其方法 |
| CN121816424A (zh) * | 2023-08-11 | 2026-04-07 | 拜奥卡德联合股份公司 | 用于生产基于腺相关病毒(AAV)的载体(变体)的腺病毒E2a基因的修饰的序列 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5776468A (en) | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| PL181241B1 (pl) | 1993-11-17 | 2001-06-29 | Deutsche Om Arzneimittel Gmbh | Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| CA2302522C (en) | 1997-08-29 | 2010-08-17 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
| WO2000011140A1 (en) | 1998-08-20 | 2000-03-02 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| WO2006133911A2 (en) | 2005-06-17 | 2006-12-21 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hepatitis c virus nucleic acid vaccine |
| EP1957528B1 (en) | 2005-11-30 | 2012-11-07 | University of Copenhagen | A nucleotide vaccine |
| WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
| CN102131920B (zh) * | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| EP3552622A3 (en) | 2008-11-21 | 2019-12-04 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| BR112017026523A2 (pt) | 2015-06-12 | 2018-08-14 | Glaxosmithkline Biologicals Sa | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. |
| GB201620968D0 (en) * | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
-
2016
- 2016-12-09 GB GBGB1620968.6A patent/GB201620968D0/en not_active Ceased
-
2017
- 2017-12-07 CN CN201780074539.3A patent/CN110300597A/zh active Pending
- 2017-12-07 EA EA201991116A patent/EA201991116A1/ru unknown
- 2017-12-07 EP EP17838152.1A patent/EP3551224A1/en active Pending
- 2017-12-07 BR BR112019010906A patent/BR112019010906A2/pt not_active IP Right Cessation
- 2017-12-07 WO PCT/IB2017/057738 patent/WO2018104911A1/en not_active Ceased
- 2017-12-07 KR KR1020197018883A patent/KR20190092471A/ko not_active Ceased
- 2017-12-07 AR ARP170103442A patent/AR110502A1/es unknown
- 2017-12-07 CA CA3045973A patent/CA3045973A1/en active Pending
- 2017-12-07 US US16/466,683 patent/US11414679B2/en active Active
- 2017-12-07 MX MX2019006725A patent/MX2019006725A/es unknown
- 2017-12-07 JP JP2019530815A patent/JP2020511114A/ja active Pending
- 2017-12-07 AU AU2017371944A patent/AU2017371944B2/en not_active Ceased
- 2017-12-07 BE BE2017/5910A patent/BE1025029B1/fr not_active IP Right Cessation
-
2019
- 2019-05-28 IL IL266942A patent/IL266942A/en unknown
-
2022
- 2022-05-11 US US17/742,221 patent/US11795478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020511114A (ja) | 2020-04-16 |
| US20190300905A1 (en) | 2019-10-03 |
| GB201620968D0 (en) | 2017-01-25 |
| US11414679B2 (en) | 2022-08-16 |
| AU2017371944A1 (en) | 2019-06-20 |
| IL266942A (en) | 2019-07-31 |
| MX2019006725A (es) | 2019-08-22 |
| CA3045973A1 (en) | 2018-06-14 |
| US20220275397A1 (en) | 2022-09-01 |
| AR110502A1 (es) | 2019-04-03 |
| US11795478B2 (en) | 2023-10-24 |
| CN110300597A (zh) | 2019-10-01 |
| BE1025029A1 (fr) | 2018-10-02 |
| WO2018104911A1 (en) | 2018-06-14 |
| KR20190092471A (ko) | 2019-08-07 |
| EP3551224A1 (en) | 2019-10-16 |
| BE1025029B1 (fr) | 2018-10-10 |
| AU2017371944B2 (en) | 2020-07-02 |
| BR112019010906A2 (pt) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991116A1 (ru) | Полинуклеотиды и полипептиды аденовируса | |
| EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
| MX2020013553A (es) | Polinucleotidos y polipeptidos de adenovirus. | |
| MX2017016101A (es) | Polinucleotidos y polipetidos de adenovirus. | |
| BR112018001683A2 (pt) | adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano. | |
| EA201791426A1 (ru) | Полипептид и иммуномодуляция | |
| PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
| EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
| EA201892006A1 (ru) | Aav-опосредованная экспрессия с использованием синтетического промотора и энхансера | |
| EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
| EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
| EA201991546A1 (ru) | Антигенсвязывающие белки против нейропилина и способы их применения | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор | |
| EA201990884A1 (ru) | АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| MX2021014856A (es) | Vacuna de tgf-beta. | |
| EA202091104A1 (ru) | Аденовирус и пути его применения | |
| MX2018007352A (es) | Moduladores de la actividad del complemento. | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| EA202090184A3 (ru) | Пептидные композиции и способы использования | |
| KR102248420B9 (ko) | miR-142-3p의 표적 서열을 포함하는 재조합 벡터 | |
| EA201891138A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| EA201790503A1 (ru) | Полипептиды, обладающие ксиланазной активностью, с большой глубиной переработки полисахаридов, содержащих ксилозу | |
| EA201891141A1 (ru) | Новые антиангиогенные слитые полипептиды |